ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis
Completed
Eisai Inc.
Phase 3
The purpose of this study is to compare eritoran tetrasodium and placebo in patients with
severe sepsis and to demonstrate a reduction of mortality from all causes.
A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors
Terminated
Eisai Inc.
Phase 1
This is a study designed to assess the safety of administration of up to 3 dose levels of
eritoran in subjects undergoing or scheduled to undergo allogeneic bone marrow transplant
(BMT). An allogeneic BMT is the transplantation of blood stem cells taken from the bone
marrow or blood of another person.
The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects
Terminated
Nicolas Musi
Phase 2
To determine whether pharmacologic inhibition of Toll-like receptor 4 (TLR4) with eritoran
for injection (E5564) will reduce inflammation and improve glucose metabolism in insulin
resistant (obese and T2DM) subjects.
The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects
Terminated
The University of Texas Health Science Center at San Antonio
Phase 2
To determine whether pharmacologic inhibition of Toll-like receptor 4 (TLR4) with eritoran
for injection (E5564) will reduce inflammation and improve glucose metabolism in insulin
resistant (obese and T2DM) subjects.
The Role of TLR4 on Lipid-induced Insulin Resistance
Completed
The University of Texas Health Science Center at San Antonio
Phase 2
The purpose of this study is to determine whether pharmacologic inhibition of Toll-like
receptor 4 (TLR4) with eritoran for injection (E5564) prevents lipid-induced insulin
resistance in lean, normal glucose tolerant (NGT) subjects.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.